Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBIT (2016 - 2025)

Ocular Therapeutix has reported EBIT over the past 13 years, most recently at -$69.8 million for Q4 2025.

  • Quarterly results put EBIT at -$69.8 million for Q4 2025, down 37.93% from a year ago — trailing twelve months through Dec 2025 was -$270.0 million (down 57.19% YoY), and the annual figure for FY2025 was -$270.0 million, down 57.19%.
  • EBIT for Q4 2025 was -$69.8 million at Ocular Therapeutix, down from -$68.7 million in the prior quarter.
  • Over the last five years, EBIT for OCUL hit a ceiling of -$17.8 million in Q1 2022 and a floor of -$69.8 million in Q4 2025.
  • Median EBIT over the past 5 years was -$21.1 million (2022), compared with a mean of -$34.0 million.
  • Biggest five-year swings in EBIT: rose 11.84% in 2022 and later crashed 152.25% in 2024.
  • Ocular Therapeutix's EBIT stood at -$18.0 million in 2021, then dropped by 7.27% to -$19.4 million in 2022, then dropped by 3.56% to -$20.0 million in 2023, then crashed by 152.25% to -$50.6 million in 2024, then crashed by 37.93% to -$69.8 million in 2025.
  • The last three reported values for EBIT were -$69.8 million (Q4 2025), -$68.7 million (Q3 2025), and -$67.6 million (Q2 2025) per Business Quant data.